CD8-positive central memory T-cell (Tcm) (Tcm)

CD8-positive central memory T-cells (Tcm) are a specialized subset of long-lived memory T lymphocytes that play a pivotal role in the adaptive immune system's ability to respond to recurring pathogens and tumors [PMID: 10506554]. Defined by the surface expression of CD8, CD45RO, and the lymphoid homing markers CCR7 and CD62L, these cells lack immediate cytotoxic effector functions but possess high proliferative capacity and the ability to persist long-term in the absence of antigen [PMID: 25154371]. Upon re-exposure to their specific antigen, Tcm cells rapidly expand and differentiate into effector memory and terminal effector cells that execute direct cell killing [PMID: 21725288]. In the context of biotechnology and immunotherapy, Tcm cells are considered a primary focus for the development of adoptive cell therapies, such as CAR-T and TCR-engineered T-cells, because their superior engraftment and metabolic fitness are strongly associated with sustained therapeutic responses [PMID: 27622333]. Various pharmacological agents, including recombinant cytokines like Interleukin-15 (IL-15) and Interleukin-7 (IL-7) or AKT inhibitors, are utilized during the ex vivo manufacturing process to enrich or maintain the Tcm phenotype to improve clinical efficacy [PMID: 28249852].

Other names

CD8+ TcmCentral memory CD8+ T lymphocyteCCR7+ CD62L+ CD8+ T-cellAntigen-experienced CD8+ T-cell

Drugs typically interact with these cells by signaling through cytokine receptors (e.g., IL-2R, IL-15R) to promote expansion and survival, or by blocking inhibitory checkpoint receptors (e.g., PD-1, CTLA-4) to prevent exhaustion and maintain their metabolic and proliferative fitness.